Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
12.2
売上高前年同期増減率（%）Wording
Conditional
How definitive the wording is.Results for this period
First quarter2025年4月1日〜2025年6月30日ConsolidatedJapanese GAAPNet Sales2,496¥ millionYear on year +12.2%Progress 24.2%
Operating profit281¥ millionYear on year +28.7%Progress 21.6%
Ordinary income287¥ millionYear on year -33.7%Progress 21.5%
Net income attributable to owners of the parent174¥ millionYear on year -38.0%Progress 19.2%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share15.05円
Financial position at period-end
Total assets12,553¥ million
of which net assets 5,600 ¥ millionEquity ratio 44.6%vs. prior year-end -1.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueBiomaterials Business ¥1,827,489 thousand (YoY +13.7%), Resource-Circulation Business ¥408,327 thousand (YoY +8.3%), Other Businesses ¥369,214 thousand (YoY +2.6%)
Segment profitBiomaterials Business ¥261,332 thousand (YoY +11.3%), Resource-Circulation Business ¥23,810 thousand, Other Businesses ¥2,542 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥10,322 million (YoY +10.0%)
Operating profit¥1,303 million (YoY +13.1%)
Ordinary income¥1,335 million (YoY -6.8%)
Net income¥905 million (YoY -12.4%)
Annual Dividend Forecast¥28 → ¥30（+7.1%）
Factors Behind Changes in Business Performance
バイオマテリアル事業は原料調達数量の増加に伴う生産量増加、新規顧客獲得・既存顧客のシェアアップ、調達単価改定の効果により増収増益。資源循環事業は営業活動により取扱数量が前年同期比118.2％となり、その他事業は不要物流機器の買取やリユース・リニューアルサービスに注力。
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name None / Excluded Number of companies 0 / Company name None
Material subsequent events2025年7月25日に、譲渡制限付株式報酬として当社普通株式17,800株を処分し、払込が完了しました。処分価額の総額は19,900,400円です。
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥3,805 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥257 thousand
Depreciation and amortization¥158,106 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNone (対象者：Not applicable)
Issued Shares at Period-End11,779,600
Treasury Shares at Period-End204,408
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年4月1日〜2025年6月30日 |
| Net Sales | ¥2,496 million (YoY +12.2%) |
| Operating profit | ¥281 million (YoY +28.7%) |
| Ordinary income | ¥287 million (YoY -33.7%) |
| Profit attributable to owners of the parent | ¥174 million (YoY -38.0%) |
| Net income per share | 15.05円 |
| Equity ratio | End of the current fiscal period 44.6 / End of previous period 45.9 |
| Total assets | ¥12,553 million |
| Net assets | ¥5,600 million |
| Full-year earnings forecast | Net Sales ¥10,322 million (YoY +10.0%) / Operating profit ¥1,303 million (YoY +13.1%) / Ordinary income ¥1,335 million (YoY -6.8%) / Net income ¥905 million (YoY -12.4%) |
| Annual Dividend Forecast | ¥28 → ¥30（+7.1%） |
| Segment revenue | Biomaterials Business ¥1,827,489 thousand (YoY +13.7%), Resource-Circulation Business ¥408,327 thousand (YoY +8.3%), Other Businesses ¥369,214 thousand (YoY +2.6%) |
| Segment profit | Biomaterials Business ¥261,332 thousand (YoY +11.3%), Resource-Circulation Business ¥23,810 thousand, Other Businesses ¥2,542 thousand |
| Depreciation and amortization | ¥158,106 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥3,805 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥257 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name None / Excluded Number of companies 0 / Company name None |
| Material subsequent events | 2025年7月25日に、譲渡制限付株式報酬として当社普通株式17,800株を処分し、払込が完了しました。処分価額の総額は19,900,400円です。 |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 11,779,600 |
| Treasury Shares at Period-End | 204,408 |
| Factors Behind Changes in Business Performance | バイオマテリアル事業は原料調達数量の増加に伴う生産量増加、新規顧客獲得・既存顧客のシェアアップ、調達単価改定の効果により増収増益。資源循環事業は営業活動により取扱数量が前年同期比118.2％となり、その他事業は不要物流機器の買取やリユース・リニューアルサービスに注力。 |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.バイオマテリアル事業では原料調達数量の増加、新規顧客の獲得・既存顧客のシェアアップ、調達単価改定の効果などにより増収増益となりました。資源循環事業では営業活動により取扱数量が前年同期比118.2％となり、その他事業では物流資材のリユース・リニューアルサービスなどに注力しました。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.